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The nucleotide sequence of the unique neutralizing monoclonal antibody D32.10 raised against a
conserved conformational epitope shared between E1 and E2 on the serum-derived hepatitis C virus
(HCV) envelope was determined. Subsequently, the recombinant single-chain Fv fragment (scFv)
was cloned and expressed in Escherichia coli, and its molecular characterization was assessed using
multi-angle laser light scattering. The scFv mimicked the antibody in binding to the native serum-
derived HCV particles from patients, as well as to envelope E1E2 complexes and E1, E2 glycoproteins
carrying the viral epitope. The scFv D32.10 competed with the parental IgG for binding to antigen,
and therefore could be a promising candidate for therapeutics and diagnostics.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) infects an estimated 2–3% of the world
population and is a major cause of chronic liver disease. The major-
ity (80%) of infected individuals progress to chronic hepatitis thatincreases their risk for developing cirrhosis and hepatocellular car-
cinoma [1]. The standard of care (SOC) therapy for chronic infec-
tion uses a combination of pegylated interferon-a (PEG-IFN) and
ribavirin (RBV), which is effective in only 50% of treated patients
infected and has many side effects. Two new direct-acting antivi-
rals (DAAs) targeting the virus protease NS3 have recently been ap-
proved for triple therapy with PEG-IFN and RBV to improve success
rates and to shorten treatment [2]. This approach to treatment still
suffers a number of drawbacks: regimen restricted to patients with
genotype 1, and increased rate of adverse effects. There is therefore
a pressing need to develop alternative anti-HCV therapies, particu-
larly in the arena of prophylactic or therapeutic vaccines. The
observation that some HCV-infected individuals (20%) can resolve
spontaneously infection with virus-speciﬁc immune responses
[3] has spurred interest in the potential of HCV vaccines, but as
yet no such vaccine exists. Progress toward this goal has been ham-
pered by a number of factors, in particular the extreme genetic
diversity of HCV (six major genotypes and more than 50 subtypes)
[4]. Therefore, identiﬁcation of protective conserved immune epi-
topes of the virus is essential for understanding the role of neutral-
izing responses in disease pathogenesis, and for developing
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that the mouse monoclonal antibody (mAb) D32.10 recognizes a
unique discontinuous antigenic determinant encompassing one se-
quence in the E1 glycoprotein (aa 297–306), and two sequences in
the E2 glycoprotein: E2A (aa 480–494) and E2B (aa 608–62) juxta-
posed on the surface of native circulating enveloped HCV particles,
designated HCVsp, in chronic hepatitis C patients [5,6]. This epi-
tope is highly conserved between the different genotypes of HCV
(1a, 1b, 2a, 2b, 3a, 4, 5 and 6). Furthermore, the mAb D32.10 is
so far the only antibody able to efﬁciently inhibit the interactions
between HCVsp and hepatocytes [7] as well as in vitro HCV infec-
tion [8]. The relevance of this mAb in vivo was proven by using the
D32.10 epitope as a probe to look for the presence of anti-E1E2A,B
D32.10 epitope-binding antibodies in the serum of HCV-infected
patients. We demonstrated that unique anti-E1E2 neutralizing
antibodies were associated with spontaneous recovery or predic-
tive of sustained virological response (SVR) in patients with
chronic hepatitis C [9].
Recombinant antibody (rAb) technologies involving the han-
dling of key antibody domains constitute an option and have been
increasingly used as alternatives to mAbs in medical diagnostic
and therapeutic applications. One of the most popular types of
rAbs is single-chain variable fragment (scFv) as it has been success-
fully modiﬁed into a number of different antibody formats and is
easily expressed by several expression systems [10]. We reported
here the nucleotide sequence of the gene segments encoding the
variable domains of D32.10, and described the cloning and expres-
sion of a scFv construction of the antibody. The antigen-binding
properties of scFv D32.10 with those of the native antibody were
compared.
2. Materials and methods
2.1. mAb D32.10 puriﬁcation and N-terminal sequencing
Secreted IgGs (isotype IgG1, j) were puriﬁed from the D32.10
hybridoma culture by precipitation with 75% ammonium sulfate,
then by afﬁnity chromatography on a Protein A-Sepharose column.
After elution, a gel ﬁltration on Sephadex-200 was carried out. The
resulting protein was loaded on 12% SDS gels and transferred to a
PVDF membrane. N-terminal sequencing of the heavy and light
bands on the membrane was performed by standard Edman degra-
dation using a model 492 sequencing system (Applied Biosystems)
followed by identiﬁcation using a model 140C HPLC (Applied
Biosystems) and analysis using the Model 610A (V2.1) software
(Applied Biosystems). The following N-terminal protein sequences
were found: (i) for the light chain: D-V-V-M-T-Q-T (ii) for the hea-
vy chain: E-V-K-L-V-E-S.
2.2. Bioinformatics analysis and primers design
The above-described protein sequences were compared to the
whole murine repertoire of variable domains available (www.img-
t.org). The cDNA sequences of all the variable domains starting
with these protein sequences were aligned and compared, andTable 1
List of primers used to sequence D32.10 VH, VL and to generate synthetic g
dotted and solid lines, respectively. The linker serine-glycine (Gly4Serine)3
Primers Sequences (50–>30)
H1 CGGAATTCATGAGGTG
L1 CGGAATTCATGATGTTG
polyT30 CTCGAGAAGCTTTTTTT
H1revlink ACCACCGGATCCGCCTC
L1forlink GGCGGAGGCGGATCCG
L1revXho ATGCCTCGAGCTAAGCColigonucleotide primers matching this alignment were designed.
The alignment showed only one different cDNA sequence for each
chain, so one oligonucleotide was designed for each chain: (i) for
the ﬁrst light chain (L1): cgg a att cat GAT GTT GTG ATG ACC
CAG ACT CCA; (ii) for the ﬁrst heavy chain (H1): cgg a att cat
GAG GTG AAG CTG GTG GAG TCT GGG GGA, wherein the sections
in lower case letters correspond to restriction enzyme sites intro-
duced in the oligonucleotides for cloning purposes, and the sec-
tions in capital letters correspond to the cDNA derived sequences
corresponding to the protein sequence determined by N-terminal
sequencing. In addition to these forward primers, a common re-
verse primer based on a polyT sequence was also designed, includ-
ing enzyme sequences and ordered (polyT30 ctc gag aag cttTTT TTT
TTT TTT TTT TTT TTT TTT TTT TTT –) (Table 1).
2.3. RNA Isolation, cDNA Ampliﬁcation and Sequencing
Total RNA was extracted from 106 fresh hybridoma cells using
the RNeasy mini kit (Qiagen) and cDNA was generated by reverse
transcription using SuperScript III First-Strand Synthesis Super-
Mix kit (Invitrogen) and the polyT primer. The cDNA was ampliﬁed
by PCR using the speciﬁc and polyT primers described above and
the Phusion High-Fidelity PCR master mix (Finnzymes). The PCR
was performed on a MasterCycler (Eppendorf), and resulting PCR
products were puriﬁed using the QIAquick PCR puriﬁcation kit
(Qiagen) and sequenced by Euroﬁns MWG biotech. Finally PCR
products were cloned into the pPROEX HTb vector (Life Technolo-
gies) and sequenced by using L1 and H1 primers (Table 1).
2.4. Cloning and expression of the scFv D32.10
A set of new primers were designed to amplify the light chain
variable region (VL) and the heavy chain variable region (VH) genes
and to add special tags as restriction enzymes, (Gly4Ser)3 linker
and a stop codon [11]. The VL gene was ampliﬁed with the primers
L1forlink and L1revXho (Table 1) and the VH gene with the primers
H1 and H1revlink (Table 1) to generate D32.10 scFv synthetic gene
by splice overlapped extension. A clone pPROEX HTb-scFv D32.10
has been used to transform competent Escherichia coli BL21-Gold
(Stratagene) and cultivated in LB medium supplemented with
100 lg/ml ampicillin at 37 C to an optical density (OD) of 0.4–
0.6 at 600 nm. After 4 h of 1 mM IPTG induction at 37 C, the cells
were harvested by centrifugation and suspended in 20 mM Tris–
HCl at pH 8 and 150 mM NaCl (Tris–NaCl buffer) before sonication
for 5 min (60% ampliﬁcation). The resulting bacterial extract was
centrifuged (20,000 rpm for 30 min at 4 C), the pellet resuspended
in 20 mM Tris–HCl at pH 8 and 2 M NaCl and centrifuged again.
The resulting pellet was solubilized in Tris–NaCl buffer containing
0.1% Triton-X100, centrifuged, washed by resuspension/centrifuga-
tion and solubilized in denaturation buffer (100 mM Tris–HCl at pH
8, 500 mM NaCl, 8 M urea). The ﬁnal extract was centrifuged again
and the supernatant subjected to immobilized metal afﬁnity chro-
matography (IMAC) using Ni-NTA resin (Qiagen) for puriﬁcation of
the scFv (Fig. 1). The puriﬁed scFv was diluted 50 times in refolding
buffer (100 mM Tris pH 9, 500 mM NaCl, 5% glycerol, 250 mMenes encoding scFv D32.10. The restriction sites XhoI and EcoRI are in
is in bold letters.
AAGCTGGTGGAGTCTGGGGGA
TGATGACCCAGACTCCA
TTTTTTTTTTTTTTTTTTTTTTTTT
CGCCAGAGACAGTGACCAGCGTCCC
GTGGTGGCGGATCTGGAGGTGGCGGAGATGTTGTGATGACCCAGACT
CGTTTTATTTCCAACTT
Fig. 1. scFv D32.10 puriﬁcation (using a Ni2+-charged column). Control of the
puriﬁed His-tagged scFv D32.10 by 10% SDS–PAGE after Coomassie staining. Lane 1,
crude cell extract; Lanes 2, 3 and 4, eluates with 300 mM imidazole. MW, Molecular
Weight markers in kilodaltons (kDa).
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2 mM reduced glutathione, 1 mM oxidized glutathione) for
30 min. A FLPC (Biologic DuoFlow system, Biorad) was performed
using a commercially packed high resolution 10/30 Superdex 75
column equilibrated with 100 mM Tris at pH 9 and 500 mM NaCl.
2.5. Antigen-binding and competitive binding of scFv
Two different HCV RNA-positive enriched pellet preparations or
HCVsp (HCV-Fan, genotype 1a/2a; HCV-Lat, genotype 3) prepared
as previously described from two different HCV chronically-in-
fected patients [6,7] were used as antigenic probes in dot blot
and western blot experiments for testing the scFv D32.10 recogni-
tion to natural complete HCV particles, to E1E2 envelope com-
plexes and to E1 and E2 proteins. For dot blot assay, the HCV
preparations (HCVsp-Fan and HCVsp-Lat, 5 lg of protein) were
spotted onto nitrocellulose paper. The immunoblotting was per-
formed by incubation overnight at 4 C with either 5 lg/ml of
mouse IgGs D32.10 or 10 lg/ml of scFv D32.10 as the primary anti-
bodies. Mouse IgGs or scFv bound were detected by incubation for
1 h with peroxydase-conjugated anti-mouse immunoglobulins (di-
luted 1/10 000) or anti-His-tag (diluted 1/5000) as the secondary
antibodies (Sigma–Aldrich). For competitive binding experiments,
a mixture of a constant amount of IgG D32.10 (5 lg/ml) and
increasing amounts of scFv D32.10 (10, 20 or 50 lg/ml) diluted
in PBS, supplemented with 0.02% BSA and 0.05% Tween 20, were
added for 1 h of incubation. Conversely, a mixture of a constant
amount of scFv D32.10 (10 lg/ml) and increasing amounts of IgG
D32.10 (5, 10, 20, 50 lg/ml) diluted in the same conditions were
added for 1 h of incubation. Spots were then visualized by
chemiluminescence detection using SuperSignal West Pico
Luminol/Enhancer solution (Thermo Scientiﬁc). DensitometricFig. 2. Encoded amino acid sequence of the scFv D32.10. The red color show the VH domai
D32.10. Framework (FR) and CDR were in solid and dotted lines, respectively.measurement was performed by using ImageJ 1.43u software
(National Institute of Health, USA).
For western blotting assay, the preparations (HCVsp-Fan and
HCVsp-Lat, 5 lg of protein) were subjected to SDS–PAGE under
reducing or non-reducing conditions (2% SDS ± 5% 2-ME). After
transfer, the mouse IgGs D32.10 (10 lg/ml) or scFv (20 lg/ml) di-
luted in TBS-Tween-5% milk were added as primary antibodies.
The revelation phase was performed using peroxydase-conjugated
anti-mouse or anti-His-tag antibodies.
To assess the speciﬁcity of the antibody staining (IgG and scFv
D32.10), normal human serum (NHS) was used as control probe
in both dot and western blot experiments. His-tag protein was
used as positive control for revelation using anti-His tag
antibodies.
2.6. Biophysics characterization and structure determination
Online MALLS detection was performed with a DAWN-HELEOS
II detector (Wyatt Technology, Santa Barbara, CA, United States).
Data were analyzed, and weight-averaged molecular masses (Mw)
were calculated using the ASTRA software (Wyatt Technology,
Santa Barbara, CA, United States). The S75 Superdex column (GE
Healthcare) was equilibrated with 100 mM Tris at pH 9 containing
500 mM NaCl.
3. Results
3.1. Production, puriﬁcation and structure of the scFv D32.10
The nucleotide sequence obtained from the rearranged V region
genes of D32.10 is shown in Fig. S1 (Supplementary data) and was
deposited at EMBL (European Bioinformatics Institute, United
Kingdom) with WEBIN ID number Hx2000032426. The scFv was
constructed by introducing the 15-residue linker, (Gly4Ser)3, con-
necting the C-terminus of VH to the N-terminus of VL (Fig. 2). The
recombinant protein contains a hexahistidine tail to facilitate puri-
ﬁcation and identiﬁcation. An induction of 4 h at 37 C with 1 mM
IPTG was performed. The ﬁnal crude bacterial extract (Fig. 1, lane
1) was subjected to puriﬁcation by denaturing IMAC chromatogra-
phy, and SDS–PAGE analysis of fractions showed that elution of the
protein was obtained at 300 mM imidazole in quite pure form
(Fig. 1, lanes 2, 3 and 4). The yield of recombinant scFv was
10 mg/L of culture medium corresponding to the scFv present in
the starting material. Although the molecular weight (MW) was
estimated from the sequence to be 29.6 kDa, SDS–PAGE analysis
gave an apparent MW of approximately 28 kDa.
In order to determine the oligomeric state in solution of the
scFv, a western blotting assay (Fig. 3B) and a multiangle laser light
scattering study (MALLS) (Fig. 3C) were performed on renatured
and gel ﬁltration puriﬁed products (Fig. 3A). Fig. 3A showed one
large shoulder (numbered as 1 & 2) and two peaks (numbered 3
& 4). The corresponding fractions were subjected to SDS–PAGE
and western blotting in reducing (R) and non-reducing (NR) condi-
tions (Fig. 3B). Under NR conditions, Fig. 3B, lanes 1 and 2 showedn of D32.10, the black color the linker (Gly4Ser)3, and the blue color the VL domain of
Fig. 3. Analysis of the puriﬁed scFv D32.10 by using MALLS methodology. After
puriﬁcation of the scFv on high resolution 10/30 Superdex 75 column (A), the
fractions 1, 2, 3 and 4 were subjected to SDS–PAGE (B) under reducing (R) and non-
reducing (NR) conditions, and the fraction 3 was analyzed by MALLS (C).
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peaks 1 and 2, respectively. Only scFv monomers were detected
in the fractions 3 under both NR and R conditions (Fig. 3B).Fig. 4. Cross-competition of scFv with the parental IgG D32.10. Dot blot experiments with
His tag protein (4) as positive control for anti-Histag antibodies. (A) Competition with inPossibly, the fraction 2 may also contain functional non-covalent
dimers or diabodies [10]. The results achieved by MALLS conﬁrmed
that the fraction 3 is pure and consists of a homogenous mono-
meric scFv D32.10 species with a MW of 30–33 kDa (Fig. 3C).
3.2. The scFv speciﬁcally recognizes serum-derived HCV particles
(HCVsp), E1E2 envelope complexes and E1, E2 glycoproteins and
competes with the full IgG
Two HCVsp isolates, from patient 1 with genotype (GT) 3, and
from patient 2 with two distinct GT1a and 2a [12], were used in
dot blot experiments for their recognition by IgG D32.10 as posi-
tive controls in comparison with the scFv. As shown in Fig. 4, IgGs
and scFv D32.10 speciﬁcally and strongly reacted with both HCVsp
isolates, whereas did not react with NHS used as control probe
(Fig. 4A and B, lanes 0). As the native antibody, the scFv showed
a higher reactivity with the HCVsp isolate 1 (HCV-Lat, GT3) than
with the HCV isolate 2 (HCV-Fan, GT1a/1b), independently of the
genotype but dependent on surface pattern of HCV particles
[6,7]. It is worth noticing that the scFv signiﬁcantly inhibited in a
concentration-dependent manner the binding of IgG D32.10 to
both HCVsp isolates (>50% for the isolate 1 and >70% for the isolate
2 at a concentration of 50 lg/ml corresponding to a molecular ratio
IgG/scFv = 2) (Fig. 4A). Conversely, IgG D32.10 inhibited the bind-
ing of scFv to both HCVsp isolates in a concentration-dependent
manner with a complete (100%) inhibition at a concentration of
50 lg/ml for the isolate 1 and at a concentration of 20 lg/ml for
the isolate 2 (Fig. 4B). This supports that the scFv and full IgG mol-
ecule of D32.10 recognize the same epitope and exhibit similar
binding afﬁnities to antigen.
The monoclonal antibody D32.10 has been shown to also react
with large E1E2 complexes and E1 and E2 glycoproteins [5]. There-
fore, using the same HCVsp isolates as antigenic probes, the HCV
polypeptide speciﬁcity of scFv D32.10 was tested by western blot
analysis (Fig. 5) under non-reducing (NR) and reducing (R) condi-
tions. When the two GT3 and GT1a/2a isolates (corresponding to
lanes 1 and 2, respectively) were analyzed under NR conditions
(Fig. 5A), scFv D32.10 recognized disulﬁde-linked complexes
recovered in the upper part of the gel (P250 kDa) as IgG D32.10.
These high MW bands likely correspond to hetero-oligomeric
E1E2 complexes [6,13]. Under R conditions (Fig. 5B), scFv D32.10
recognized two (HCVsp GT1a/2a, lane 2) or three (HCVsp GT3, lane
1) bands at 31 kDa, 62 kDa and around 100 kDa, corresponding to
E1, E2, and heterodimer E1E2, respectively. Same patterns were
observed with IgGs D32.10. No reactivity was detected with NHS
(lanes 3) as control antigenic probe. As positive control, His tag
protein (lane 4) was detected by anti-His tag antibodies.two HCVsp isolates 1 (GT3) and 2 (GT1a/2a), NHS as control antigenic probe (3) and
creasing amounts of scFv. (B) Competition with increasing amounts of parental IgG.
Fig. 5. scFv D32.10 reactivity with serum-derived HCV E1E2 proteins. Western blot with two HCVsp isolates (lanes 1, GT3 & lanes 2, GT1a/2a), NHS (lanes 3) and His tag
protein (lanes 4) as control probes, tested under NR (A) and R (B) conditions. Immunoblotting was performed using IgG or scFv D32.10. The molecular masses of markers are
indicated in kilodaltons (kDa).
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same HCV E1E2 antigenic speciﬁcity as the native antibody.
4. Discussion
The scFv construction of anti-HCV E1E2 D32.10 mAb is func-
tional since it recognizes serum-derived HCV 1a/2a and HCV 3a
particles, as well as large E1E2 complexes and E1 and E2 glyco-
proteins [5–7]. Moreover, it competes with D32.10 IgG for bind-
ing to antigen. By using size-exclusion chromatography
associated with light-scattering, we show that the scFv D32.10
forms misfolded dimers and oligomers as frequently observed
with scFv constructions, but functional well-refolded monomers
are in great majority.
HCV envelope glycoproteins, which are involved in HCV entry
into host cells, represent the major targets of neutralizing antibod-
ies (nAbs). To date the majority of neutralizing mAbs against HCV
infection target conserved regions on E2 [14]. Mapping of neutral-
ization epitopes on the HCV E2 protein sequence showed that nAbs
to linear epitopes targeted a segment adjacent to HVR1, encom-
passing aa 410–425 as the mouse mAb AP33 having contact resi-
dues within aa 412–423 [15,16], and to conformational epitopes
targeted mainly two discontinuous regions, aa 424–443 and aa
523–540 [15]. However, the 412-423 epitope appeared to be
weakly immunogenic and AP33-like antibodies are less prevalent
in HCV-infected patients suggesting that such nAbs do not play a
major role in natural clearance of HCV infection [17]. Moreover,
AP33-escape mutants arose under selection pressure and are resis-
tant to AP33-mediated neutralization [18].The anti-HCV E1E2 mAb D32.10 is the unique antibody ob-
tained by immunization with HCV particles isolated from infected
patients. Epitope mapping identiﬁed the D32.10 epitope being
formed by three well-conserved discontinuous E1 (aa 297–306)
and E2 segments (aa 480–494 and aa 613–621), obviously highly
immunogenic and juxtaposed on the surface of native circulating
enveloped HCV particles (HCVsp) in chronic hepatitis C patients
[5,6]. Unlike well-characterized anti-HCV E2 human mAbs with
potent cross-neutralizing activity, D32.10-like antibodies have
been shown to be associated with spontaneous virus clearance
and predictive for complete viral response in chronically-infected
patients under SOC antiviral therapy [9]. The E1E2 epitope targeted
by the D32.10 mAb has been shown to be preferentially involved in
interactions between the virus and polarized hepatocytes [7]. In
the recently proposed 3D-model of HCV E2 ectodomain (E2e)
[19], the E2 segment, aa 613–621, recognized by D32.10 encom-
passed residues 613–618 important for CD81 binding. The E2 seg-
ment, aa 480–494, also recognized by D32.10 encompasses a
highly conserved stretch of residues stabilized by disulphide
bridge 3 (Cys486–Cys494). This segment was close to the putative
highly conserved fusion peptide, which may also form a contact
with E1 glycoprotein [19]. Obviously, these three segments which
composed the discontinuous antigenic determinant identiﬁed by
the D32.10 mAb were exposed and physically very close in the
quaternary structure of the E1E2 envelope glycoprotein complexes
expressed on the surface of natural HCVsp of all genotypes.
The unique properties of mAb D32.10 highlighted the relevance
of developing D32.10-based anti-HCV therapy. Therefore, this
study was conducted to generate a scFv more convenient to use
3340 C. Fallecker et al. / FEBS Letters 587 (2013) 3335–3340than the full-length mAb, for medical applications. Here, we dem-
onstrate that the scFv D32.10 fragment with a VH-linker-VL orien-
tation is expressed mainly as functional forms. Indeed, it binds
native HCVsp as well as E1 and E2 antigens and signiﬁcantly inhib-
its the binding of the IgG D32.10 to HCVsp. Therefore, it efﬁciently
recognizes the same epitope than the original parental mAb. Future
studies should include investigations in in vitro neutralization as-
say and in vivo animal models to enhance the therapeutic applica-
bility of this scFv, especially in the issue of HCV reinfection after
liver transplantation.
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